The Dynamics of Dopamine D2 Receptor-Expressing Striatal Neurons and the Downstream Circuit Underlying L-Dopa-Induced Dyskinesia in Rats

Neurosci Bull. 2023 Sep;39(9):1411-1425. doi: 10.1007/s12264-023-01054-5. Epub 2023 Apr 6.

Abstract

L-dopa (l-3,4-dihydroxyphenylalanine)-induced dyskinesia (LID) is a debilitating complication of dopamine replacement therapy for Parkinson's disease. The potential contribution of striatal D2 receptor (D2R)-positive neurons and downstream circuits in the pathophysiology of LID remains unclear. In this study, we investigated the role of striatal D2R+ neurons and downstream globus pallidus externa (GPe) neurons in a rat model of LID. Intrastriatal administration of raclopride, a D2R antagonist, significantly inhibited dyskinetic behavior, while intrastriatal administration of pramipexole, a D2-like receptor agonist, yielded aggravation of dyskinesia in LID rats. Fiber photometry revealed the overinhibition of striatal D2R+ neurons and hyperactivity of downstream GPe neurons during the dyskinetic phase of LID rats. In contrast, the striatal D2R+ neurons showed intermittent synchronized overactivity in the decay phase of dyskinesia. Consistent with the above findings, optogenetic activation of striatal D2R+ neurons or their projections in the GPe was adequate to suppress most of the dyskinetic behaviors of LID rats. Our data demonstrate that the aberrant activity of striatal D2R+ neurons and downstream GPe neurons is a decisive mechanism mediating dyskinetic symptoms in LID rats.

Keywords: D2 receptor; Dyskinesia; Fiber photometry; Levodopa; Optogenetics; Parkinson’s disease.

MeSH terms

  • Animals
  • Antiparkinson Agents / toxicity
  • Corpus Striatum / metabolism
  • Dopamine
  • Dyskinesia, Drug-Induced*
  • Levodopa / toxicity
  • Neurons / metabolism
  • Oxidopamine
  • Parkinsonian Disorders* / drug therapy
  • Rats
  • Receptors, Dopamine D2 / metabolism

Substances

  • Levodopa
  • Dopamine
  • Oxidopamine
  • Receptors, Dopamine D2
  • Antiparkinson Agents